BCBA/MRNA (BCBA/MRNA)
Buenos Aires Stock Exchange: BCBA/MRNA · ARS
ARS 18,690
+640.75 (+3.5%)· Recorded snapshot
| Market cap | 131.5T | |
|---|---|---|
| Revenue (ttm) | 3.3T | |
| Net income (ttm) | -4.7T | |
| EPS (ttm) | -ARS 650 | |
| Volume | 148,747 |
Market data
Price
Recent price action with selectable time range.
Financial snapshot
- Revenue (ttm)
- 3.3T
- Net income (ttm)
- -4.7T
- EPS (ttm)
- -ARS 650
- Market cap
- 131.5T
Fair-value bridge
- Current price
- ARS 18,690
In the news
Latest news · BCBA/MRNA
Recent company headlines from major financial publishers.
Valuation
- Market cap
- 131.5T
- P/S
- 39.8x
- P/B
- 13.1x
Profitability
- Gross margin
- -66.0%
- Operating margin
- -109.3%
- ROE
- -39.0%
- ROA
- -13.3%
- ROIC
- -76.0%
Balance sheet
- Debt / equity
- 0.19
- Current ratio
- 2.29
- Quick ratio
- 2.07
Trading
- Volume
- 148,747
Calendar
Next earnings
Upcoming earnings date and setup when available.
Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector percentile context
Refreshed 2026-10-29 19:55 UTC
Forward P/En/a
P25 n/aP50 n/aP75 n/a
Trailing P/En/a
P25 n/aP50 n/aP75 n/a
ROE-39
P25 n/aP50 n/aP75 n/a
ROIC-76
P25 n/aP50 n/aP75 n/a
Benchmarks · 1M
S&P 500+0.6%
Nasdaq Composite-2.3%
Dow Jones Industrial Average+1.9%
Russell 2000+1.8%
All BCBA/MRNA indicators
Market & fundamental data
Available fields
170
Groups with data
10
Currency
USD
Showing 170 of 170 available metrics for this ticker.
Deeper analysis on BCBA/MRNA
14 sections in the full report · jump straight to what you need
Forecast
Base and Bull forecast paths with report-date return framing.
Valuation
Fair-value bridge, DCF, owner earnings, and peer multiples.
Sensitivity
Cost-of-equity and terminal-growth stress table.
Risks
Kill scenarios, soft-pass flags, and downside catalysts.
Earnings
Next earnings setup and beat / inline / miss thresholds.
Position sizing
Entry, exit, conviction, and quarterly monitoring rules.
Financials
Revenue, margins, cash flow, and balance-sheet context.
Peers
Relative valuation and profitability against the cohort.
Moat
Economic-profit evidence and competitive advantage risk.
Industry cycle
Sector phase, capital cycle, and secular tailwinds.
Scorecard
Six-factor overlay and 9-category weighted scorecard.
Recommendation
Final action, action steps, opportunity, and biggest risk.
Perspectives
Growth, value, and income investor reads.
Archive
Prior published reports and rating changes.
Frequently asked questions
About this BCBA/MRNA report
Is a complete BCBA/MRNA research report available?
No complete published report is available for bcba/MRNA (BCBA/MRNA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.